Michael P. Thirlwell

Montreal, QC, Canada

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications

Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer.

Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer.

Journal: Breast (Edinburgh, Scotland)
Published: October 18, 2022

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019.

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019.

Journal: Current oncology (Toronto, Ont.)
Published: April 30, 2021

NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab.

NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab.

Journal: NPJ breast cancer
Published: October 29, 2020

Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial.

Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 05, 2020

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2018.

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2018.

Journal: Current oncology (Toronto, Ont.)
Published: November 12, 2019

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 08, 2018

Eastern Canadian Colorectal Cancer Consensus Conference 2017.

Eastern Canadian Colorectal Cancer Consensus Conference 2017.

Journal: Current oncology (Toronto, Ont.)
Published: August 17, 2018

Corrigendum: Eastern Canadian Gastrointestinal Cancer Consensus Conference 2014.

Corrigendum: Eastern Canadian Gastrointestinal Cancer Consensus Conference 2014.

Journal: Current oncology (Toronto, Ont.)
Published: August 19, 2016

Eastern Canadian Colorectal Cancer Consensus Conference 2013: emerging therapies in the treatment of pancreatic, rectal, and colorectal cancers.

Eastern Canadian Colorectal Cancer Consensus Conference 2013: emerging therapies in the treatment of pancreatic, rectal, and colorectal cancers.

Journal: Current oncology (Toronto, Ont.)
Published: March 12, 2016

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2014.

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2014.

Journal: Current oncology (Toronto, Ont.)
Published: August 25, 2015

Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study.

Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study.

Journal: Breast cancer research and treatment
Published: November 23, 2014

Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma.

Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma.

Journal: Annals of surgical oncology
Published: February 15, 2014
Showing 1-12 of 18

Last Updated: 09/26/2026